Physician profile
Anthony Defranzo
NPI 1073598017
$3,952.69
in general payments reported to CMS, 2019-2025
11 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2021: $97.08 · 2022: $449 · 2023: $965 · 2024: $1,467 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,510 · Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,509.99 |
| Food and Beverage | $281.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $2,509.99 | 2023-2025 | |
| Sientra, INC. | $343.19 | 2022 | |
| Mentor Worldwide LLC | $246.99 | 2019 | |
| Solventum Corporation | $146.87 | 2025 | Prevena |
| Davol INC. | $134.87 | 2023 | Arista Ah Flexitip |
| Polarityte, INC. | $114.74 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $108.10 | 2019 | |
| Tei Biosciences INC | $106.19 | 2019 | |
| Axogen | $106.01 | 2022 | |
| Integra Lifesciences Corporation | $97.08 | 2021 | |
| Tei Medical INC. | $38.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Defranzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.